FDA warns kratom sellers to stop making unproven claims about chronic pain, opioid addiction benefits

| | July 8, 2019
Image: Rattiya Thongdumhyu/Shutterstock
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

The Food and Drug Administration is still pressing down hard on kratom—the plant treatment that adherents say has helped them manage their opioid addiction or chronic pain. [June 25] the agency announced it was sending warning letters to two online marketers and distributors, accusing them of illegally selling kratom products with false or unproven claims about their health benefits.

These claims, detailed by the FDA in its warning letters to the two firms, include that kratom can help with opioid addiction or pain relief, but also go as far as to suggest that it can treat arthritis, insomnia, and even cancer.

“Despite our warnings, companies continue to sell this dangerous product and make deceptive medical claims that are not backed by science or any reliable scientific evidence,” Ned Sharpless, the current acting FDA chief, said in a statement. “As we work to combat the opioid crisis, we cannot allow unscrupulous vendors to take advantage of consumers by selling products with unsubstantiated claims that they can treat opioid addiction or alleviate other medical conditions.”

Read full, original post: FDA Is Going After Kratom, Warning Companies to Stop Selling It for Opioid Addiction and Cancer

Related article:  How the brains of different dog breeds have evolved to meet our needs
Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend